

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Birgit K. Jaitner et al.
Filed : June 25, 2003
For : SOS1 INHIBITORS
Docket No. : 59516-275 / PP-18707.002
Date : June 25, 2003

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Form PTO/SB/08 (Copies of the cited reference are enclosed). As to the references supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such references, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are being made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Express Mail No. EL852691467US

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.


Respectfully submitted,

Davis Wright Tremaine LLP



27476

PATENT TRADEMARK OFFICE


Jane E. R. Potter
Registration No. 33,332

2600 Century Square
1501 Fourth Avenue
Seattle, WA 98101-1688
Phone: (206) 622-7650
Fax: (206) 628-7699

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			
		Application Number	
		Filing Date	June 25, 2003
		First Named Inventor	Birgit K. Jaitner
		Art Unit	
		Examiner Name	
Sheet	1	of	1
		Attorney Docket Number	59516-275 / PP-18707.002

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HART, T.C., <i>A Mutation in the SOS1 Gene Causes Hereditary Gingival Fibromatosis Type 1</i> , AM. J. HUM. GENET. 70:943-954, 2002	
		NYHUS, J.K., <i>Direct in vivo Transfection of Antisense Fas-ligand Reduces Tumor Growth and Invasion</i> , GENE THERAPY 8:209-214, 2001	
		QIAN, X. et al., <i>The Sos1 and Sos2 Ras-specific Exchange Factors: Differences in Placental Expression and Signaling Properties</i> , THE EMBO JOURNAL 19:642-654, 2000	
		SIBILIA, M. et al., <i>The EGF Receptor Provides an Essential Survival Signal for SOS-Dependent Skin Tumor Development</i> , CELL 102:211-220, 2000	
		BRANCH, A.D., <i>A Good Antisense Molecule is Hard to Find</i> , TIBS 23:45-50, 1998	
		ANAZODO, M.I. ET AL., <i>Relative Levels of Inhibition of p24 Gene Expression by Different 20-mer antisense Oligonucleotide Sequences Targeting Nucleotides +1129 to +1268 of the HIV-1 gag Genome: an Analysis of Mechanism</i> , BIOCHEM. BIOPHYS. RES COMMUN. 229:305-309, 1996	
		HIROTA, Y. et al., <i>p53 Antisense Oligonucleotide Inhibits Growth of Human Colon Tumor and Normal Cell Lines</i> , JPN. J. CANCER RES. 87:735-742, 1996	
		GILES, R.V. et al., <i>Single Base Discrimination for Ribonuclease H-Dependent Antisense Effects Within Intact Human Leukemia Cells</i> , NUCLEIC ACIDS RESEARCH 23:954-961, 1995	
		GISHIZKY, M.L., <i>Tyrosine Kinase Induced Mitogenesis. Breaking the Link with Cancer</i> , IN ANNUAL REPORTS IN MEDICINAL CHEMISTRY 30:247-253 (Academic Press, Inc., 1995)	
		PANDEY, P. et al., <i>Association of the DF3/MUC1 Breast Cancer Antigen with Grb2 and the Sos/Ras Exchange Protein</i> , CAN RES. 55:4000-4003, 1995	
		WITTY, J.P. et al., <i>Modulation of Matrolysin Levels in Colon Carcinoma Cell Lines Affects Tumorigenicity in vivo</i> , CAN. RES. 54:4805-4812, 1994	
		HASELHOFF, J. et al., <i>Simple RNA enzymes with New and Highly Specific Endoribonuclease Activities</i> , NATURE 334:585-591, 1988	
		WALBOT, V. et al., <i>Plant Development and Ribozymes for Pathogens</i> , NATURE 334:196-197, 1988	
		FORSTER, A.C. et al., <i>Self-Cleavage of Plus and Minus RNAs of a Virusoid and a Structural Model for the Active Sites</i> , CELL 49:211-220, 1987	
		UHLENBECK, O.C., <i>A Small Catalytic Oligoribonucleotide</i> , NATURE 328:596-600, 1987	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Arlington, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Arlington, VA 22313-1450.